Signature Estate & Investment Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Signature Estate & Investment Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,595	Closed	-$1.11M	–	694
2026 Q1	$1.11M	Sell	6,595 -20	-0.3%	-$3.42K	0.02%	253
2025 Q4	$1.12M	Sell	6,615 -62	-0.9%	-$10.1K	0.02%	241
2025 Q3	$964K	Sell	6,677 -424	-6%	-$57.9K	0.02%	252
2025 Q2	$898K	Sell	7,101 -1,756	-20%	-$216K	0.02%	250
2025 Q1	$1.13M	Sell	8,857 -425	-5%	-$57.6K	0.03%	194
2024 Q4	$1.23M	Buy	9,282 +381	+4%	+$53.6K	0.03%	186
2024 Q3	$1.3M	Buy	8,901 +669	+8%	+$96.8K	0.03%	169
2024 Q2	$1.13M	Buy	+8,232	New	+$1.1M	0.03%	180

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Signature Estate & Investment Advisors's IBB Position: Q2 2026 in Review

Signature Estate & Investment Advisors sold out of iShares Biotechnology ETF (IBB) in Q2 2026, closing a stake of 6,595 shares — an estimated $1.11M sold.

Signature Estate & Investment Advisors first reported a position in IBB in Q2 2024 and held it in 8 quarters. The position peaked at $1.3M in Q3 2024. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Signature Estate & Investment Advisors reported no remaining iShares Biotechnology ETF position as of Q2 2026 after selling out during the quarter.
Signature Estate & Investment Advisors sold 6,595 iShares Biotechnology ETF shares in Q2 2026, an estimated $1.11M.
Signature Estate & Investment Advisors first reported a position in iShares Biotechnology ETF in Q2 2024 and held it in 8 quarters.
Signature Estate & Investment Advisors's iShares Biotechnology ETF position peaked at $1.3M in Q3 2024.
954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Signature Estate & Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.